Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Scienture Holdings, Inc. (SCNX)
USD0.41
+0.02 (+4.16%)
US NASDAQ Healthcare Medical - Healthcare Information Services
Address
6308 Benjamin Rd 33634
Tampa, FL, US
Tampa, FL, US
CEO
Shankar Hariharan
Website
trxadehealth.com
IPO
2014-02-06
CIK 1382574 ISIN US80880X1046
Description
As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.41
+0.02 (+4.16%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
411.7K
Beta
3.14
Float Shares
7.92M
Free Float %
51.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.95% | +2.81% | +2.03% | +0.75% | -31.39% | -20.98% | -57.53% | -94.62% | -94.62% | -94.62% | -94.62% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.41
DCF (Unlevered)
41.87
+10,233.9%
DCF (Levered)
43.25
+10,572.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-1.57
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Healthcare Information Services: +14.2%+215.9% ★ Q1'26: +548,983.6% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%-208.9% Q1'26: +75.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-10,214.3% Q1'26: -5,182.9% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%-9,134.2% Q1'26: -6.2% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%-0.1% Q1'26: 0.0% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+4,100.6% Q1'26: +4,210.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×-0.62× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.91M
est: 4.96M (-41.3%)
|
2.48M
est: 7.72M (-67.8%)
|
2.93M
est: 2.93M (+0.0%)
|
3.83M
est: 3.50M (+9.6%)
|
7.44M
est: 4.19M (+77.5%)
|
17.12M
est: 19.36M (-11.5%)
|
9.89M
est: 9.60M (+3.0%)
|
10.25M
est: 11.43M (-10.3%)
|
1.36M
est: 8.93M (-84.7%)
|
136.6K
est: 9.30M (-98.5%)
|
431.6K
est: 600.3K (-28.1%)
|
5.07M
5.07M – 5.07M
+744.1% YoY
|
17.22M
17.22M – 17.22M
+239.8% YoY
|
37.98M
37.98M – 37.98M
+120.6% YoY
|
52.68M
52.68M – 52.68M
+38.7% YoY
|
67.63M
67.63M – 67.63M
+28.4% YoY
|
| EBITDA |
-133.3K
est: -2.82M (+95.3%)
|
-1.02M
est: -4.39M (+76.7%)
|
446.0K
est: -1.67M (+126.8%)
|
66.6K
est: -1.99M (+103.3%)
|
-136.5K
est: -2.38M (+94.3%)
|
-2.40M
est: -11.01M (+78.2%)
|
-5.15M
est: -5.46M (+5.6%)
|
-1.87M
est: -6.50M (+71.2%)
|
-6.29M
est: -5.08M (-23.8%)
|
-17.39M
est: -6.89M (-152.4%)
|
-38.93M
est: -444.7K (-8,655.1%)
|
-3.75M
-3.75M – -3.75M
-744.1% YoY
|
-12.75M
-12.75M – -12.75M
-239.8% YoY
|
-28.13M
-28.13M – -28.13M
-120.6% YoY
|
-39.02M
-39.02M – -39.02M
-38.7% YoY
|
-50.10M
-50.10M – -50.10M
-28.4% YoY
|
| EBIT |
-137.1K
est: -2.86M (+95.2%)
|
-1.02M
est: -4.45M (+77.0%)
|
446.0K
est: -1.69M (+126.4%)
|
66.6K
est: -2.02M (+103.3%)
|
-231.2K
est: -2.42M (+90.4%)
|
-2.51M
est: -11.16M (+77.5%)
|
-5.29M
est: -5.54M (+4.4%)
|
-2.07M
est: -6.59M (+68.6%)
|
-7.34M
est: -5.15M (-42.5%)
|
-17.44M
est: -6.95M (-151.0%)
|
-39.42M
est: -448.6K (-8,687.3%)
|
-3.79M
-3.79M – -3.79M
-744.1% YoY
|
-12.87M
-12.87M – -12.87M
-239.8% YoY
|
-28.38M
-28.38M – -28.38M
-120.6% YoY
|
-39.37M
-39.37M – -39.37M
-38.7% YoY
|
-50.55M
-50.55M – -50.55M
-28.4% YoY
|
| Net Income |
-1.12M
est: -8.22M (+86.4%)
|
-2.76M
est: -23.02M (+88.0%)
|
289.0K
est: 3.29M (-91.2%)
|
9.0K
est: 3.29M (-99.7%)
|
-284.4K
est: 6.58M (-104.3%)
|
-2.54M
est: -1.10M (-131.4%)
|
-5.32M
est: -38.91M (+86.3%)
|
-3.47M
est: -19.46M (+82.2%)
|
-17.84M
est: -3.84M (-365.1%)
|
9.07M
est: -69.06M (+113.1%)
|
-41.51B
est: -187.24M (-22,071.0%)
|
-110.50M
-110.50M – -110.50M
+41.0% YoY
|
-32.23M
-32.23M – -32.23M
+70.8% YoY
|
35.30M
35.30M – 35.30M
+209.5% YoY
|
75.20M
75.20M – 75.20M
+113.0% YoY
|
113.57M
113.57M – 113.57M
+51.0% YoY
|
| SGA |
2.86M
est: 92.45M (-96.9%)
|
3.34M
est: 143.93M (-97.7%)
|
1.41M
est: 54.66M (-97.4%)
|
3.47M
est: 65.18M (-94.7%)
|
4.38M
est: 78.14M (-94.4%)
|
7.49M
est: 360.98M (-97.9%)
|
7.54M
est: 179.02M (-95.8%)
|
6.57M
est: 213.07M (-96.9%)
|
4.35M
est: 166.59M (-97.4%)
|
12.05M
est: 44.71B (-100.0%)
|
10.33B
est: 2.89B (+258.1%)
|
24.36B
24.36B – 24.36B
+744.1% YoY
|
82.76B
82.76B – 82.76B
+239.8% YoY
|
182.57B
182.57B – 182.57B
+120.6% YoY
|
253.21B
253.21B – 253.21B
+38.7% YoY
|
325.12B
325.12B – 325.12B
+28.4% YoY
|
| EPS |
-3.21
est: -2.25 (-42.7%)
|
-7.87
est: -6.30 (-24.9%)
|
0.90
est: 0.90 (+0.0%)
|
0.03
est: 0.90 (-97.2%)
|
-0.72
est: 1.80 (-140.0%)
|
-4.94
est: -0.30 (-1,546.7%)
|
-9.80
est: -10.65 (+8.0%)
|
-6.15
est: -5.33 (-15.5%)
|
-23.35
est: -1.05 (-2,123.8%)
|
2.69
est: -0.45 (+697.8%)
|
-2.70
est: -1.22 (-121.3%)
|
-0.72
-0.72 – -0.72
+41.0% YoY
|
-0.21
-0.21 – -0.21
+70.8% YoY
|
0.23
0.23 – 0.23
+209.5% YoY
|
0.49
0.49 – 0.49
+113.0% YoY
|
0.74
0.74 – 0.74
+51.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-13.38B
OE per share TTM
-87.75
Owner's Yield
-8,172.74%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
92.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
8
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Suren Ajjarapu | 14.15M | 45.30% | 10.10M | 4.05M | 10.10M | 10.00 | IN | United States | 2014-12-31 | ↗ |
| 2 | Prashant Patel | 12.25M | 39.30% | 9.75M | 2.50M | 9.75M | 10.00 | IN | United States | 2014-12-31 | ↗ |
| 3 | Sandhya Ajjarapu | 4.05M | 13.00% | — | 4.05M | — | 10.00 | OO | United States | 2014-12-31 | ↗ |
| 4 | Amudha Mahendiran | 2.84M | 8.57% | — | 2.84M | — | 10.00 | IN | United States | 2017-01-12 | ↗ |
| 5 | Gajan Mahendiran | 2.84M | 8.57% | — | 2.84M | — | 10.00 | IN | United States | 2017-01-12 | ↗ |
| 6 | Rina Patel | 2.50M | 8.00% | — | 2.50M | — | 10.00 | OO | United States | 2014-12-31 | ↗ |
| 7 | Armistice Capital, LLC | 977.1K | 9.99% | — | 977.1K | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 8 | Steven Boyd | 977.1K | 9.99% | — | 977.1K | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 164.7K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-20 | Shankar Hariharan | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.00001 | 500,000 | 0.00 | — | 3,518,679 | D | ↗ |
| 2026-02-20 | Narasimhan Mani | Director / Officer | A-Award | A | Common Stock, par value $0.00001 | 500,000 | 0.00 | — | 1,550,000 | D | ↗ |
| 2025-10-01 | Shankar Hariharan | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.00001 | 300,000 | 0.00 | — | 3,018,679 | D | ↗ |
| 2025-10-01 | Narasimhan Mani | Director / Officer | A-Award | A | Common Stock, par value $0.00001 | 300,000 | 0.00 | — | 1,050,000 | D | ↗ |
| 2025-04-14 | Shankar Hariharan | Director / Officer / 10% Owner | A-Award | A | Common Stock, par value $0.00001 | 750,000 | 0.00 | — | 2,718,679 | D | ↗ |
| 2025-04-14 | Narasimhan Mani | Director / Officer | A-Award | A | Common Stock, par value $0.00001 | 750,000 | 0.00 | — | 750,000 | D | ↗ |
| 2025-03-10 | Shankar Hariharan | Director / Officer / 10% Owner | J-Other | D | Common Stock, par value $0.00001 | 30,000 | 0.00 | — | 1,968,679 | D | ↗ |
| 2025-03-10 | Narasimhan Mani | Director / Officer | J-Other | D | Common Stock, par value $0.00001 | 20,000 | 0.00 | — | 1,395,515 | I | ↗ |
| 2024-09-19 | Shankar Hariharan | Director / Officer / 10% Owner | C-Conversion | D | Series X Non-Voting Convertible Preferred Stock | 356,480 | 0.00 | — | 0 | I | ↗ |
| 2024-09-19 | Narasimhan Mani | Director / Officer | C-Conversion | D | Series X Non-Voting Convertible Preferred Stock | 1,357,538 | 0.00 | — | 0 | I | ↗ |
Executive team
Top executives
EBIT / Employee
-28.2K
Shares Outstanding
15.41M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Surendra Ajjarapu Former Chairman of the Board, Chief Executive Officer, and Secretary | 484.2K | — | 25.0K | — | — | 60.9K | 570.6K | 4.38% | ↗ |
| 2 | 2024 | Prashant Patel Former President, Chief Operating Officer, and Interim Principal Financial/ Accounting Officer | 333.0K | — | 76.5K | — | — | — | 409.5K | 18.68% | ↗ |
| 3 | 2023 | Surendra Ajjarapu Former Chairman of the Board, Chief Executive Officer, and Secretary | 360.0K | — | 243.1K | — | — | 24.9K | 628.0K | 38.71% | ↗ |
| 4 | 2023 | Prashant Patel Former President, Chief Operating Officer, and Interim Principal Financial/ Accounting Officer | 150.0K | — | 43.7K | — | — | — | 193.7K | 22.54% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eric Michael Sherb | Chief Financial Officer | 82.5K | male |
| Eric Sherb | Chief Financial Officer | 82.5K | male |
| Michele Rath | Senior Vice President & Chief Commercial Officer of Scienture LLC | — | female |
| Narasimhan Mani | President, Co-CEO & Director | — | — |
| Rahul Surana | Executive Vice President & Chief Operating Officer of Scienture LLC | — | male |
| Shankar Hariharan | Founder, Co-CEO & Executive Chairman | — | — |
ESG Rating
ESG Score History MEDICAL - HEALTHCARE INFORMATION SERVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SCNX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
